Role of vascular mechanisms involved in the acute gastric mucosal injury induced by droxicam and piroxicam in rats by Martín Calero, María José et al.
Pharmaceutical Sciences 1997, 3: 137-141 
Received January 20, 1997 
Accepted February 12, 1997 
0 1997 Pharmaceutical Sciences 
Role of Vascular Mechanisms Involved in the Acute Gastric 
Mucosal Injury Induced by Droxicam and Piroxicam in Rats 
M .  J .  MARTIN CALERO,  c .  ALARCON DE LA LASTRA, J .  R .  A V I L A ,  v .  MOTILVA, I .  LUQUE, 
J .  ESTEBAN* A N D  J .  M. HERRERIAS* 
Laboratorio de Farmacologia, Facultad de F a m c i a ,  Universidad de Sevilla, and *Departamento de 
Medicina Intema, Servicio de Aparato Digestivo, Hospital Universitario Virgen Macarena, Sevilla, Spain 
Abstract 
We describe the formation of severe gastric erosions produced in fasted rats by intragastric 
administration of droxicam and its active species piroxicam, non-steroidal anti-inflamma- 
tory drugs of the oxicam group. The time course of gastric damage and the possible role of 
mucus secretion, changes of gastric vascular permeability, and neutrophil activation in the 
development of droxicam- and piroxicam-induced astric lesions, were also investigated. 
Both drugs dose-dependently (1-25-20 mg kg - ) caused acute gastric haemorrhagic 
erosions in the rat. These lesions were significantly greater with piroxicam treatment 6 h 
after dosing. Only the lower doses of droxicam and piroxicam (1.25 mg kg-') induced a 
significant increase of mucus gel production at different times (3 and 6 h). However, there 
was no increase in the concentration of its components. Oral pretreatment of the animals 
with either agent did not induce any changes on the values of mucosal vascular 
permeability. In contrast, myeloperoxidase activity as an index of neutrophil infiltration 
was significantly increased. A marked relationship was found between the lesion index and 
myeloperoxidase activity. 
These results suggest that neutrophil infiltration could play an important role in the 
pathogenesis of gastric mucosal injury induced by these oxicam agents. 
? 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
have been a mainstay in the treatment of inflam- 
matory diseases such as rheumatoid arthritis. 
However, the long-term use of these drugs is 
associated with significant adverse effects, most 
notably gastric ulceration, bleeding and perforation. 
A number of different strategies have been used to 
obtain NSAIDs with reduced gastric toxicity. These 
include formulating the agents with an enteric 
coating to prevent absorption in the stomach, and 
the development of prodrugs, which are not active 
until they have undergone metabolism in the liver, 
and so prevent the imtant properties of these drugs 
on the gastric mucosa. 
Members of the oxicam family are not carboxylic 
acids, but they are acidic by virtue of their enolic 4- 
hydroxy substituent. Droxicam is a prodrug that 
after oral administration is hydrolysed to pirox- 
icam, the active species, in the gastrointestinal tract 
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before absorption (Martinez & Sanchez 1991). 
Piroxicam, like droxicam, has shown anti-inflam- 
matory, analgesic and antipyretic activity, but after 
its administration the haemorrhagic lesions of the 
gastric mucosa occurred in about 20% of osteoar- 
thritis patients. Both the beneficial and detrimental 
effects of oxicams are likely to be attributable to 
the ability of these drugs to suppress prostaglandin 
synthesis (Bohl et a1 1990). 
Recently, a vascular aetiology for NSAID gas- 
tropathy has been proposed, based on the demon- 
strable ability of these agents to cause vascular 
endothelial damage, local decrease in mucosal 
blood flow and activation of polymorphonuclear 
leucocytes (Wallace et al 1990). The aim of the 
present work was to study the possible role of 
vascular mechanisms involved in the formation of 
gastric erosions produced by oral administration of 
droxicam compared with piroxicam, such as mod- 
ifications of vascular permeability and increase in 
neutrophil infiltration. Thus, we can determine 
whether its formulation as a prodrug induces a 
protective effect on the gastric mucosa of the rat. 
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Materials and Methods 
Animals, groups, and drug preparation 
Male and female Wistar rats, 180-250 g were 
placed in single cages in a controlled room (tem- 
perature 22-24°C and humidity 70-75%). The 
animals were deprived of food for 24 h before the 
experiments, but had free access to water. They 
were randomly assigned to groups and were treated 
with droxicam (1-25, 5.0, 10.0, 20.0 and 
40-0 mg kg-' body weight, Esteve SA, Barcelona, 
Spain) and piroxicam (1.25, 5.0, 10.0 and 
20.0 mg kg-' body weight, Pfizer SA, Madrid, 
Spain), respectively. The agents were suspended in 
1% Tween 20 and were administered by the intra- 
gastric route (1 mL/100 g body weight). Control 
groups received vehicle in a comparable volume. 
Gastric mucosal injury. Biochemical study of 
gastric mucus 
Groups of 8-10 rats each were treated with drox- 
icam and piroxicam, and were killed at 3 and 6 h, 
respectively, using an overdose of anaesthetic, and 
their stomachs removed and opened along the 
greater curvature. Briefly, the length and width of 
each lesion was measured and the product was 
expressed in terms of the ulcer index (UI, mm2). 
The gastric mucus gel was obtained by scraping the 
surface of the mucosa with a glass slide and was 
immediately homogenized in 4 mL of distilled 
water. The weight of mucus (g) was the difference 
between the weight of homogenate and that of the 
original 4 mL of water. Total proteins (mg mL- ') 
were determined from one portion of the homo- 
genate (1 mL), following the colorimetric techni- 
que of Lowry et a1 (1951). The hexosamine content 
(pg mL-') was determined as described by Escolar 
et a1 (1987). The doses that produced 50 and 80% 
of the gastric damage were calculated by the 
graphic method (UI plotted against log dose), and 
were chosen for the main experiments (droxicam: 
12.5 and 20.4 mg kg-', piroxicam: 3.7 and 
8.5 mg kg-', respectively). The minimum dose 
required to cause gastric damage (1 -25 mg kg- I )  
was also used. The duration of the ulcerogenic 
effect of both drugs was examined after intragastric 
administration of the dose giving 80% of the gastric 
lesions at various intervals (3, 6 and 9 h). 
Determination of microvascular permeability 
The microvascular permeability was evaluated 6 h 
after treatment, by measuring the extravasated 
amount of the dye Evan's blue in the mucosa 
(Takeuchi et a1 1987). The rats were anaesthetized 
with sodium pentothal (Abbott SA, 60 mg kg-'). 
Then, 1 mL 1 %  Evan's blue was injected intrave- 
nously 30 min before the animal was killed. The 
stomach was removed, opened along the greater 
curvature and placed in pre-weighed tubes with 
9 mL formamide. The dye was extracted in for- 
mamide at 65°C for 12 h and quantified by light 
absorbance at 620 nm (Perkin Elmer Lambda 3). 
The amount in the tissue ( p g  (mg tissue)-') was 
calculated from a standard curve. 
Assessment of leucocyte involvement 
Neutrophil infiltration in-vivo has previously been 
assessed by measuring granulocyte-specific 
enzymes such as myeloperoxidase in tissue (Gri- 
sham et a1 1990). Myeloperoxidase activity in this 
experimental model was measured in new groups 
of animals 6 h after treatment with droxicam (1.25, 
12.5 and 20.4 m k -' and piroxicam (1-25, 3.7 
Briefly, one sample from corpus gastric was 
obtained from each animal. Samples were excised 
and rapidly rinsed with ice-cold saline. The tissue 
was thawed, weighed and homogenized in 10 
volumes 50 m~ phosphate buffered saline pH 7.4. 
The homogenate was centrifuged at 20 000 g, 
20 min, 4°C. The pellet was again homogenized in 
10 volumes 50 m~ phosphate buffered saline pH 
6-0 containing 0.5 % hexadecyltrimethylammonium 
bromide (HETAB) and 10 m~ EDTA. The 
HETAB-containing homogenate was subjected to 
one cycle of freezing and thawing and a brief 
period of sonication. A sample of homogenate 
(0.5 pL) was added to a 0.5-mL reaction volume 
containing 80 m~ phosphate buffered saline pH 
5.4, 0.5% HETAB and 1-6 m~ 3,3',5,5'-tetra- 
methylbenzidine. The mixture was incubated at 
37°C for 5 min and the reaction started by the 
addition of 0.3 m~ H202. 
Each tube containing the complete reaction 
mixture was incubated for exactly 3 min at 37°C. 
The reaction was terminated by the sequential 
addition of catalase (20 pg mL-') and 2 mL 0.2 M 
sodium acetate pH 3-0. The changes in absorbance 
at 655 nm were measured spectrophotometrically. 
One unit of myeloperoxidase activity was defined 
as the amount of enzyme present that produced a 
change in absorbance of 1-0 min-' at 37°C in the 
final reaction volume containing the acetate. 
and 8.5 mg kg- B g )  ). 
Blood leucocyte counts 
New groups of animals were used for leucocyte 
counts. Animals were anaesthetized by inhalation 
of diethyl ether 3-6 h after dosing with droxicam, 
piroxicam or vehicle. The thorax was opened and 
approximately 2 mL of blood was withdrawn by 
cardiac puncture (using a 21 -gauge butterfly nee- 
dle) and added to vials containing EDTA as an 
anticoagulant. Blood smears were prepared and 
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examined microscopically for leucocyte counts 
using a Neubauer camera. Blood counts were 
assessed by an observer unaware of the treatment. 
Statistical analysis 
Values are given as arithmetic means f s.e.m. 
Differences between groups were analysed using 
the Mann-Whitney U-test (changes in ulcer index, 
UI) and the Student’s t-test for unpaired data. 
Results 
All animals tested showed gastric erosions 3 and 
6 h after drug administration. Piroxicam (1.25- 
10.0 mg kg-’) produced a progressive and sig- 
nificant increase in the area of the lesions from 
0 . 2 0 f 0 . 1 4  to 1 .99f0.92 mm2 at 3 h, and 
0.21 f 0 . 1 2  to 3 . 9 2 f  1.12 mm2 at 6 h. However, 
no changes were observed on UI with the higher 
dose, 20 mg kg - ’ (2.01 f 0.87 mm2 at 3 h and 
3.96 f 0.63 mm2 at 6 h, respectively). The gastric 
damage induced by droxicam was significantly 
lower at all doses tested (Table 1). The doses that 
produced 80% of damage in gastric mucosa 
(droxicam 20.5 mg kg-’, piroxicam 8.5 mg kg-’) 
were selected for the study of the duration of the 
gastrolesive effect (3, 6 and 9 h). The surface of 
gastric mucosa affected increased up to 6 h, with 
no significant decrease uy to 9 h. The groups 
treated with 1-25 mg kg- droxicam and pirox- 
icam at 3 and 6 h showed a significant increase in 
the amount of gastric mucus compared with control 
(P < 0.01 and P < 0.001, respectively) (Table 2); 
however, there was no enhancement of quality 
(proteins and hexosamine content, data not shown). 
Mucus secretion did not change significantly with 
respect to the control group with the rest of 
treatment. Table 3 shows the Evan’s blue con- 
centration in the stomach tissue, as the criterion of 
permeability of the gastric blood vessels, after 6 h 
of droxicam and piroxicam administration. We 
observed no increase in its concentration compared 
with control animals. Table 3 also compares mye- 
loperoxidase activity as an index of neutrophil 
infiltration in control mucosal samples with those 
obtained after administration of droxicam (1.25, 
12.5 and 20.4 mg kg-’) and piroxicam (1.25, 3.7 
and 8.5 mg kg-’) at 6 h of treatment. Our 
data show that myeloperoxidase activity was 
significantly increased in a dose-dependent manner 
compared with control. These results indicate 
that there was substantial neutrophil influx into 
the mucosa in response to injury in rats. How- 
ever, in vehicle-treated animals the leucocytes 
present in blood-samples were 4.08 x 103f  
1.45 x lo3 mmp3 and their numbers remain 
Table 1. 
of droxicam and piroxicam at 3 and 6 h of treatment. 
Gastric ulcer index (mm’) after oral administration 
Treatment Dose Ulcer index (mm’) 
(mg kg-’) 
3 h  6 h  
Droxicam 1.25 
5 
10 
20 
40 
5 
10 
20 
Piroxicam 1.25 
0.13 f O . 0 4  
0.36 f 0.05 
0.84 f 0.19 
0.98 f 0.17 
1 .OO f 0.24 
0.20 f 0.14 
1.67 f 0.43* 
1.99 f 0.92 
2.01 f 0.87 
0.17 f 0.04 
0.51 f0 .15  
0.53 f 0.24 
1.35 f 0.47 
1.57 f0 .21  
0.21 f0 .12  
2.32 f 0.36*** 
3.92f 1.12*** 
3.96f 0.63** 
*P < 0.05, **P < 0.01, ***P < 0,001 compared with the 
same dose of droxicam. 
Table 2. 
tration of droxicam and piroxicam at 3 and 6 h of treatment. 
Gastric mucus secretion in rats after oral adminis- 
Treatment Dose Gastric mucus (8) 
(mg kg-l) 
3 h  6 h  
Control - 
Droxicam 1.25 
5 
10 
20 
40 
5 
10 
20 
Piroxicam 1.25 
0.085 f0.010 
0.172 f0.020** 
0.141 f 0.021 
0.123f0.013 
0.124 f 0.010 
0.112f0.016 
0.1 80 f 0.04 1 *** 
0.092 f 0.023 
0.080 f 0.0 13 
0.083 f 0.01 1 
0.079 f 0.014 
0.160 4Z 0.01 2** 
0.162 f 0.022 
0.132 f 0.020 
0.112f0.014 
0 ~ 1 1 0 ~ 0 ~ 0 1 0  
0.210 f0.040*** 
0.142 f 0.03 1 
0.111f0.014 
0.1 13 f 0,010 
**P < 0.01, ***P < 0.001 compared with control. 
Table 3. Changes in myeloperoxidase activity and mucosal 
microvascular permeability after oral administration of drox- 
icam and piroxicam at 6 h of treatment. 
Treatment Dose Myeloperoxidase Permeability 
(mg kg- 9 (%) 
~~ 
Control - 99.90 f 7.17 99.90 f 1 1.54 
Piroxicam 1.25 137.60 f 10.54** 69.19 f 8.93 
3.70 141.32f 12.16** 92.87 f 8.08 
8.50 156.29 f 24.08* 116.14 f 23.63 
Droxicam 1.25 126.25 f 5.34** 71.10 f 7.14 
12.50 133.07 f 10.68** 78.68 f 12.55 
20.24 165.81 f 9.34*** 93.24 f 11.45 
*P < 0.05, **P < 0.01, ***Pi 0.001 compared with 
control. 
essentially constant throughout the experimental 
period. Droxicam and piroxicam treatment had no 
significant effects on the number of circulating 
leucocytes after 3-6 h. 
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Discussion 
The present data show that droxicam provokes 
haemorrhagic lesions in the corpus mucosa of rats 
during a 6-h test period (1.25-40 mg kg-') 
although the damage was already observed in the 
stomach 3 h after administration. The doses which 
produce 50 and 80% of ulceration were 12.5 and 
20.4 mg kg-', respectively and these doses were 
tenfold those for piroxicam (3.7 and 
8.5 mg kg-I). These findings are in agreement 
with those of Jane & Rodriguez de la Serna 
(1991). It has been hypothesized that this fact is 
due to delayed gastric absorption; droxicam must 
undergo dissolution and hydrolysis prior to 
absorption into the gastric mucosa as piroxicam 
(Jane & Rodriguez de la Serna 1991). The patho- 
genesis of NSAID's gastropathy is poorly under- 
stood but has been causally linked to the topical 
irritation of the mucosa. Droxicam, at least theo- 
reticalIy, does not produce this effect on the sto- 
mach walls. However, the systemic effect of 
droxicam could be involved. The beneficial (anti- 
inflammatory, analgesic, antipyretic, antithrombo- 
tic) and detrimental (ulcerogenic) effects of 
NSAIDs are likely to be attributable to the ability 
of these drugs to suppress prostaglandin synthesis. 
Reduced prostaglandin production in the gastro- 
intestinal tract is thought to result in decreased 
cytoprotective mechanisms, such as mucus-bicar- 
bonate barrier stimulation or the restitution of 
microcirculation damage (Robert et al 1983). It 
has been recently shown that mammalian cells 
contain two related, but unique cyclooxygenase 
isozymes, referred to as COX-1 and COX-2. These 
studies have demonstrated that the two isozymes 
are pharmacologically distinct. COX-1 is a con- 
stitutively expressed enzyme (Simmons et a1 1991) 
and early observations indicate that it is involved 
in producing prostaglandins which regulate cel- 
lular housekeeping functions, such as gastric 
cytoprotection, vascular homeostasis and kidney 
functions. This enzyme is present in most tissues, 
such as stomach and vascular smooth muscle (De 
Witt et a1 1993). In contrast, COX-2 appears only 
to be expressed in inflamed tissue following 
exposure to growth factors, lymphokines, and 
other mediators of inflammation. Piroxicam, as 
well as other NSAIDs such as indomethacin and 
sulindac, preferentially inhibit murine COX-1 (De 
Witt et a1 1993). Thus it is possible that mucosal 
prostaglandin inhibition could also be the most 
important mechanism of droxicam-induced 
damage, since this drug is hydrolysed to piroxicam 
in the gastrointestinal tract. Other mechanisms 
involved in the pathogenesis of the NSAIDs, such 
as the depletion of mucus gel or changes on the 
vascular permeability in the gastric mucosa, seem 
not to be implicated in droxicam or piroxicam 
gastropathy. Our results show that these agents 
provoke gastric lesions but this seems not to be 
associated with a decrease of the mucus secretion. 
Indeed, the lowest gastrolesive doses, 1.25 and 
5 mg kg-I, produce a significant increase in the 
amount of gel layer. This fact could be interpreted 
as a self-defence mechanism of the gastric 
mucosa. Robert et al (1983) have shown that mild 
irritants such as 10-20% ethanol or HC1 and 
NaOH at low concentrations are cytoprotective, 
and suggest the existence of a prostaglandin- 
mediated self-defence mechanism in the stomach. 
It is possible that these drugs, at lower doses, 
produce an enhancement of mucus gel by a similar 
process, but higher doses do not induce any 
changes in this parameter. 
On the other hand, a number of previous studies 
have provided evidence for a critical role of cir- 
culating neutrophils in the pathogenesis of NSAID 
gastric erosions (Wallace et a1 1990). In particular, 
neutrophil adherence to the vascular endothelium 
appears to be one of the earliest detectable events 
after NSAID administration (Asako et al1992), and 
may account for a number of other events identified 
as important in the development of mucosal injury. 
At least three mechanisms are involved in damage 
induced by polymorphonuclear leucocytes. First, 
by production of reactive oxygen metabolites as 
neutrophil-derived free radicals are known to con- 
tribute significantly to the gastric ulceration 
induced by ethanol (Kvietys et al 1990) and they 
can influence vascular tone by accelerating the 
inactivation of endothelium-derived relaxing fac- 
tor; second, by release of proteinases that can 
contribute to gastrointestinal ulceration; and third, 
by clogging of the microvasculature and, therefore, 
exacerbating tissue ischaemia. Thus, it is possible 
to establish an association between the appearance 
of ulceration and the presence of infiltrating neu- 
trophils at the damage site. Six hours after drox- 
icam and piroxicam administration, there was a 
progressive increase in the area and severity of 
ulceration parallel to that of neutrophil infiltration; 
however, there was no significant change in the 
number of circulating leucocytes. 
In conclusion, our findings suggest that neu- 
trophil infiltration could play an important role in 
the pathogenesis of gastric mucosal injury induced 
by these oxicam agents, and that the ulcerogenicity 
produced by droxicam, under our experimental 
conditions, is less than that found for piroxicam. 
This assumption could be related, at least in part, to 
the absence of topical irritation induced by this 
prodrug. Other mechanisms such as reduction of 
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mucus secretion, or changes on mucosal micro- 
vascular permeability, seem not to be implicated in 
droxicam- or piroxicam-induced gastric damage. 
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